US20020006899A1
(en)
*
|
1998-10-06 |
2002-01-17 |
Pospisilik Andrew J. |
Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
|
ATE357509T1
(de)
*
|
1997-09-29 |
2007-04-15 |
Point Therapeutics Inc |
Stimulierung von hämatopoietischen zellen im vitro
|
DE19823831A1
(de)
*
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
DE19834591A1
(de)
*
|
1998-07-31 |
2000-02-03 |
Probiodrug Ges Fuer Arzneim |
Verfahren zur Steigerung des Blutglukosespiegels in Säugern
|
US6979697B1
(en)
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
WO2000053171A1
(en)
*
|
1999-03-05 |
2000-09-14 |
Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. |
Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
DE19940130A1
(de)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
WO2001044178A1
(en)
*
|
1999-12-17 |
2001-06-21 |
Versicor, Inc. |
Novel urea compounds, compositions and methods of use and preparation
|
PT1248604E
(pt)
*
|
2000-01-21 |
2007-01-31 |
Novartis Ag |
Associações compreendendo inibidor de dipeptidilpeptidase-iv
|
US20080076811A1
(en)
*
|
2000-01-21 |
2008-03-27 |
Bork Balkan |
Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
|
WO2001062266A2
(en)
*
|
2000-02-25 |
2001-08-30 |
Novo Nordisk A/S |
Use of dpp-iv inhibitors for the treatment of diabetes
|
US6500804B2
(en)
*
|
2000-03-31 |
2002-12-31 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
GB0010183D0
(en)
|
2000-04-26 |
2000-06-14 |
Ferring Bv |
Inhibitors of dipeptidyl peptidase IV
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
EP1950199B1
(en)
|
2000-08-10 |
2009-12-02 |
Mitsubishi Tanabe Pharma Corporation |
Proline derivatives and use thereof as drugs
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
EP1891948A1
(en)
*
|
2000-10-27 |
2008-02-27 |
Probiodrug AG |
Treatment of neurological and neuropsychological disorders
|
EP1328270A2
(en)
*
|
2000-10-27 |
2003-07-23 |
Probiodrug AG |
Method for the treatment of neurological and neuropsychological disorders
|
EP1354882A1
(en)
*
|
2000-12-27 |
2003-10-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Dipeptidyl peptidase iv inhibitor
|
BRPI0207767B8
(pt)
*
|
2001-02-24 |
2021-05-25 |
Boehringer Ingelheim Pharma |
derivados de xantina, seu uso, composições farmacêuticas, seus processos de preparação, e sais fisiologicamente aceitáveis
|
US20070293426A1
(en)
*
|
2001-04-02 |
2007-12-20 |
Hans-Ulrich Demuth |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
GB0109146D0
(en)
*
|
2001-04-11 |
2001-05-30 |
Ferring Bv |
Treatment of type 2 diabetes
|
DK1385856T3
(da)
|
2001-04-11 |
2006-05-15 |
Bristol Myers Squibb Co |
Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
|
US6944925B2
(en)
*
|
2001-06-13 |
2005-09-20 |
Ttx Company |
Articulated connector reconditioning process and apparatuses
|
ATE380175T1
(de)
|
2001-06-27 |
2007-12-15 |
Smithkline Beecham Corp |
Pyrrolidine als dipeptidyl peptidase inhibitoren
|
AU2002322344C1
(en)
|
2001-06-27 |
2006-02-16 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
DE10150203A1
(de)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Peptidylketone als Inhibitoren der DPIV
|
AU2002321135B2
(en)
*
|
2001-06-27 |
2007-11-08 |
Probiodrug Ag |
Dipepitdyl peptidase IV inhibitors and their uses as anti-cancer agents
|
US7183290B2
(en)
|
2001-06-27 |
2007-02-27 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
WO2003015768A2
(en)
*
|
2001-08-16 |
2003-02-27 |
Probiodrug Ag |
Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
CA2460512A1
(en)
|
2001-09-14 |
2003-03-27 |
Mitsubishi Pharma Corporation |
Thiazolidine derivatives and medicinal use thereof
|
WO2003033671A2
(en)
|
2001-10-18 |
2003-04-24 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
GB0125446D0
(en)
*
|
2001-10-23 |
2001-12-12 |
Ferring Bv |
Novel anti-diabetic agents
|
DE60304911D1
(de)
|
2002-02-25 |
2006-06-08 |
Eisai Co Ltd |
Xanthin-Derivate als DPP-IV-Inhibitoren
|
PL372316A1
(en)
|
2002-02-28 |
2005-07-11 |
Prosidion Limited |
Glutaminyl based dpiv inhibitors
|
EP1695970A1
(en)
*
|
2002-02-28 |
2006-08-30 |
Prosidion Limited |
Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis
|
US20030232761A1
(en)
*
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
EP1528931B1
(en)
*
|
2002-08-09 |
2008-05-07 |
Prosidion Ltd. |
Dipeptidyl peptidase iv inhibitors for decreasing the rate of chronic weight gain
|
TW200404796A
(en)
*
|
2002-08-19 |
2004-04-01 |
Ono Pharmaceutical Co |
Nitrogen-containing compound
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
*
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
DE60331747D1
(de)
*
|
2002-09-18 |
2010-04-29 |
Prosidion Ltd |
Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv)
|
US20040058876A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Torsten Hoffmann |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
|
EP1553937B1
(en)
|
2002-10-23 |
2010-06-02 |
Bristol-Myers Squibb Company |
Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
|
US7482337B2
(en)
*
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
DE10254304A1
(de)
*
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US7148246B2
(en)
|
2003-02-27 |
2006-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
|
DE10308355A1
(de)
|
2003-02-27 |
2004-12-23 |
Aventis Pharma Deutschland Gmbh |
Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308351A1
(de)
|
2003-02-27 |
2004-11-25 |
Aventis Pharma Deutschland Gmbh |
1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE10308352A1
(de)
|
2003-02-27 |
2004-09-09 |
Aventis Pharma Deutschland Gmbh |
Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
|
DE10308353A1
(de)
|
2003-02-27 |
2004-12-02 |
Aventis Pharma Deutschland Gmbh |
Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CN1894234A
(zh)
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
NZ572274A
(en)
|
2003-05-05 |
2009-06-26 |
Probiodrug Ag |
Use of effectors of glutaminyl and glutamate cyclases
|
DE602004026289D1
(de)
|
2003-05-05 |
2010-05-12 |
Probiodrug Ag |
Glutaminylcyclase-hemmer
|
ATE464889T1
(de)
|
2003-05-05 |
2010-05-15 |
Probiodrug Ag |
Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
|
WO2004099134A2
(en)
*
|
2003-05-05 |
2004-11-18 |
Prosidion Ltd. |
Glutaminyl based dp iv-inhibitors
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
KR20060041309A
(ko)
|
2003-08-13 |
2006-05-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CA2535971C
(en)
|
2003-08-20 |
2018-04-10 |
Biosite, Inc. |
Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
|
AU2004267955A1
(en)
*
|
2003-09-02 |
2005-03-10 |
Prosidion Ltd. |
Combination therapy for glycaemic control
|
JP2007505121A
(ja)
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EA010108B1
(ru)
|
2003-10-15 |
2008-06-30 |
Пробиодруг Аг |
Применение эффекторов глутаминил- и глутаматциклаз
|
DE10348023A1
(de)
*
|
2003-10-15 |
2005-05-19 |
Imtm Gmbh |
Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
|
EP1680120A2
(en)
|
2003-11-03 |
2006-07-19 |
Probiodrug AG |
Combinations useful for the treatment of neuronal disorders
|
KR20060109911A
(ko)
|
2003-11-17 |
2006-10-23 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
DE10355304A1
(de)
*
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7504423B2
(en)
|
2003-12-11 |
2009-03-17 |
Mitsubishi Tanabe Pharma Corporation |
α-amino acid derivatives and use thereof as medicines
|
AU2004298453A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Altana Pharma Ag |
Intermediates for the preparation of tricyclic dihydropyrano -imidazo -pyridines derivatives
|
ES2332920T3
(es)
|
2004-01-20 |
2010-02-15 |
Novartis Ag |
Proceso y formulacion de compresion directa.
|
CN101262851A
(zh)
*
|
2004-01-20 |
2008-09-10 |
诺瓦提斯公司 |
直接压片配方和方法
|
US7241787B2
(en)
|
2004-01-25 |
2007-07-10 |
Sanofi-Aventis Deutschland Gmbh |
Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
|
US7304086B2
(en)
|
2004-02-05 |
2007-12-04 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004009039A1
(de)
*
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
AU2004318013B8
(en)
*
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1586573B1
(en)
|
2004-04-01 |
2007-02-07 |
Sanofi-Aventis Deutschland GmbH |
Oxadiazolones, processes for their preparation and their use as pharmaceuticals
|
US7179809B2
(en)
*
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
US7439370B2
(en)
*
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
WO2005118555A1
(en)
*
|
2004-06-04 |
2005-12-15 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
ATE553077T1
(de)
*
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
Peptidaseinhibitoren
|
US20070259927A1
(en)
*
|
2004-08-26 |
2007-11-08 |
Takeda Pharmaceutical Company Limited |
Remedy for Diabetes
|
AR050615A1
(es)
|
2004-08-27 |
2006-11-08 |
Novartis Ag |
Composiciones farmaceuticas para la administracion oral
|
DE102004043944A1
(de)
*
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
*
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20060063719A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Point Therapeutics, Inc. |
Methods for treating diabetes
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1828192B1
(en)
*
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2006088129A1
(ja)
*
|
2005-02-18 |
2006-08-24 |
Mitsubishi Pharma Corporation |
プロリン誘導体の塩、またはその溶媒和物、及びその製造方法
|
EP2527337A1
(en)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
EP2356997A1
(en)
|
2005-06-06 |
2011-08-17 |
Georgetown University |
Compositions and methods for lipo modeling
|
DE102005026762A1
(de)
|
2005-06-09 |
2006-12-21 |
Sanofi-Aventis Deutschland Gmbh |
Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
ES2426345T3
(es)
|
2005-07-20 |
2013-10-22 |
Eli Lilly And Company |
Compuesto unidos en posición 1-amino
|
DE102005035891A1
(de)
*
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
BRPI0614732A2
(pt)
*
|
2005-08-11 |
2011-04-12 |
Hoffmann La Roche |
composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados
|
CA2622472C
(en)
*
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
US8222411B2
(en)
|
2005-09-16 |
2012-07-17 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
JOP20180109A1
(ar)
*
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
EP2487154B1
(en)
|
2005-10-31 |
2013-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
EP1971614A1
(en)
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
|
JP5165582B2
(ja)
*
|
2005-12-16 |
2013-03-21 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ジペプチジルペプチダーゼ−4インヒビターとメトホルミンとを組み合わせた医薬組成物
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
RS51745B
(en)
|
2006-04-11 |
2011-10-31 |
Arena Pharmaceuticals Inc. |
PROCEDURE FOR USING GPR119 RECEPTORS FOR INDENTIFICATION OF UNITS USEFUL FOR BONE WEIGHT INCREASE
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
BRPI0709984A2
(pt)
|
2006-04-12 |
2011-08-02 |
Probiodrug Ag |
inibidores de enzima
|
CA2649842C
(en)
*
|
2006-04-21 |
2015-02-17 |
Meiji Seika Kaisha, Ltd. |
Composition containing peptide as active ingredient
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
EP1852108A1
(en)
*
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
EP2021014A1
(en)
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7910747B2
(en)
|
2006-07-06 |
2011-03-22 |
Bristol-Myers Squibb Company |
Phosphonate and phosphinate pyrazolylamide glucokinase activators
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
WO2008017670A1
(en)
*
|
2006-08-08 |
2008-02-14 |
Boehringer Ingelheim International Gmbh |
Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
|
MEP8509A
(en)
|
2006-09-07 |
2011-12-20 |
|
Combination treatment for diabetes mellitus
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
KR20090088854A
(ko)
*
|
2006-09-13 |
2009-08-20 |
다케다 야쿠힌 고교 가부시키가이샤 |
2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
|
EP2099767A1
(en)
|
2006-11-01 |
2009-09-16 |
Brystol-Myers Squibb Company |
Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
|
WO2008057862A2
(en)
|
2006-11-01 |
2008-05-15 |
Bristol-Myers Squibb Company |
MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
|
WO2008055945A1
(en)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
ATE554085T1
(de)
|
2006-11-30 |
2012-05-15 |
Probiodrug Ag |
Neue inhibitoren von glutaminylcyclase
|
AU2007340129B2
(en)
|
2006-12-26 |
2012-02-02 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
EP2143443B1
(en)
|
2007-04-03 |
2014-11-19 |
Mitsubishi Tanabe Pharma Corporation |
A combination of dipeptidyl peptidase iv inhibitor and sweetener for use in the treatment of obesity
|
EP2865670B1
(en)
|
2007-04-18 |
2017-01-11 |
Probiodrug AG |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
EA201401193A1
(ru)
|
2007-06-04 |
2015-08-31 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Триарильные соединения и композиции, их содержащие
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2173717B9
(en)
*
|
2007-07-27 |
2013-06-26 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
EP2190434B1
(en)
*
|
2007-08-17 |
2019-04-17 |
Boehringer Ingelheim International GmbH |
Purin derivatives for use in the treatment of fap-related diseases
|
ES2448839T3
(es)
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2146210A1
(en)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
AU2009256157B2
(en)
|
2008-06-04 |
2014-12-18 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009158380A1
(en)
|
2008-06-24 |
2009-12-30 |
Bristol-Myers Squibb Company |
Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
EP2326326B1
(en)
*
|
2008-08-15 |
2019-10-09 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitors for use for the treatment of wound healing in diabetic patients
|
RU2011113823A
(ru)
|
2008-09-10 |
2012-10-20 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
KR101054911B1
(ko)
|
2008-10-17 |
2011-08-05 |
동아제약주식회사 |
디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
|
KR20110103968A
(ko)
|
2008-12-23 |
2011-09-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
유기 화합물의 염 형태
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
EP2475428B1
(en)
|
2009-09-11 |
2015-07-01 |
Probiodrug AG |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
WO2011060256A2
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Bilayer tablet formulations
|
EP2498759B1
(en)
|
2009-11-13 |
2018-08-01 |
AstraZeneca AB |
Immediate release tablet formulations
|
JP5798123B2
(ja)
|
2009-11-13 |
2015-10-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低質量のメトホルミン製剤
|
MX364651B
(es)
|
2009-11-27 |
2019-05-03 |
Boehringer Ingelheim Int Gmbh Star |
Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
ES2586231T3
(es)
|
2010-03-03 |
2016-10-13 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
CN102791704B
(zh)
|
2010-03-10 |
2015-11-25 |
前体生物药物股份公司 |
谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
|
WO2011127051A1
(en)
|
2010-04-06 |
2011-10-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
ES2559209T3
(es)
|
2010-04-14 |
2016-02-11 |
Bristol-Myers Squibb Company |
Nuevos activadores de la glucocinasa y métodos de uso de los mismos
|
US8581001B2
(en)
|
2010-04-16 |
2013-11-12 |
Codman & Shurtleff |
Metformin-cysteine prodrug
|
EP2560953B1
(en)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
EP2566469B1
(en)
|
2010-05-05 |
2022-12-21 |
Boehringer Ingelheim International GmbH |
Combination therapy
|
EP2585101A1
(en)
|
2010-06-24 |
2013-05-01 |
Boehringer Ingelheim International GmbH |
Diabetes therapy
|
KR20130137624A
(ko)
|
2010-09-03 |
2013-12-17 |
브리스톨-마이어스 스큅 컴퍼니 |
수용성 항산화제를 사용한 약물 제제
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US10894787B2
(en)
|
2010-09-22 |
2021-01-19 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
US20140079778A1
(en)
|
2011-02-01 |
2014-03-20 |
Astrazeneca Uk Limited |
Pharmaceutical Formulations Including An Amine Compound
|
EA201391254A1
(ru)
|
2011-03-01 |
2014-02-28 |
Синерджи Фармасьютикалз Инк. |
Способ получения агонистов гуанилатциклазы c
|
US8530670B2
(en)
|
2011-03-16 |
2013-09-10 |
Probiodrug Ag |
Inhibitors
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012145361A1
(en)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145603A1
(en)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2532506A1
(de)
|
2011-06-06 |
2012-12-12 |
Battenfeld-Cincinnati Germany GmbH |
Abzugsvorrichtung für einen Extruder
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
DK3489226T3
(da)
|
2012-11-20 |
2021-04-26 |
Lexicon Pharmaceuticals Inc |
Hæmmere for natriumglucose-cotransporter 1
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014197720A2
(en)
|
2013-06-05 |
2014-12-11 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
CN106061940A
(zh)
|
2013-11-05 |
2016-10-26 |
本古里安大学内盖夫研究发展局 |
治疗糖尿病和由其引发的并发疾病的化合物
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
JP2018123065A
(ja)
*
|
2017-01-30 |
2018-08-09 |
株式会社明治 |
インスリン分泌促進用組成物
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
JP2021530517A
(ja)
|
2018-07-19 |
2021-11-11 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
ダパグリフロジンを使用してHFpEFを処置する方法、及びダパグリフロジンを含む組成物
|
SG11202102498UA
(en)
|
2018-09-26 |
2021-04-29 |
Lexicon Pharmaceuticals Inc |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
TW202220672A
(zh)
|
2020-07-27 |
2022-06-01 |
瑞典商阿斯特捷利康公司 |
用達格列淨治療慢性腎臟病之方法
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|